Table 2.
Multivariate analysis of the correlation between clinicopathological characteristics and treatment regimens a.
| Characteristics | PH | TCH | P value | |||||
|---|---|---|---|---|---|---|---|---|
| OR | 95%CI | P value | OR | 95%CI | P value | |||
| Age (years) | <0.001 | |||||||
| ≥ 60 and < 70 | 0.002 | 0.000-0.017 | <0.001 | 0.022 | 0.004-0.132 | <0.001 | ||
| ≥ 70 | Reference | Reference | ||||||
| Tumor size stage | <0.001 | |||||||
| T1a-b | 88.841 | 12.364-638.387 | <0.001 | 3.830 | 0.934-15.710 | 0.062 | ||
| T1c | 7.516 | 1.609-35.116 | 0.010 | 1.877 | 0.769-4.585 | 0.167 | ||
| T2-3 | Reference | Reference | ||||||
| Tumor grade | 0.248 | |||||||
| I-II | 2.819 | 0.809-9.819 | 0.104 | 1.312 | 0.540-3.191 | 0.549 | ||
| III | Reference | Reference | ||||||
| ALN status | <0.001 | |||||||
| Positive | 0.007 | 0.001-0.084 | <0.001 | 0.082 | 0.028-0.240 | <0.001 | ||
| Negative | Reference | Reference | ||||||
| Ki-67 index | 0.004 | |||||||
| < 40 | 4.620 | 1.269-16.821 | 0.020 | 4.037 | 1.653-9.862 | 0.002 | ||
| ≥ 40 | Reference | Reference | ||||||
| Comorbidity | 0.023 | |||||||
| Yes | 2.960 | 0.865-10.129 | 0.084 | 3.114 | 1.334-7.272 | 0.009 | ||
| No | Reference | Reference | ||||||
Abbreviation: PH: paclitaxel plus trastuzumab; TCH: docetaxel plus carboplatin and trastuzumab; AC-TH: anthracyclines plus cyclophosphamide followed by taxanes and trastuzumab; ALN: axillary lymph node; OR: odds ratio; 95% CI: 95% confidence interval. aThe reference category for recommended treatment regimen is AC-TH.